Founding Team

C. Palani Palaniappan, Ph.D. is an accomplished global innovation executive, bringing forward disruptive innovations from bench science to bedside medicine. He was the Global R&D leader for organizations including GE Healthcare (Amersham Biosciences, Genomics and Proteomics), Thermo Fisher (Life Technologies, Cellular Analysis), Terumo Corporation (Terumo Blood and Cell Technologies, Donor/patient connected devices in blood collection & processing), Epic Sciences (Liquid Biopsy enabled from circulating tumor cells) and Quidel Ortho (Ortho Clinical Diagnostics, blood testing and blood screening).
In these roles, Palani championed many breakthrough ideas, leading to innovations touching millions of patients across the world with impactful patient health benefits and financial success to stakeholders. Palani has also been an active industry champion through Board positions in multiple organizations that are helping to shape life sciences.

Sergey Gershtein is an accomplished technology leader who excels at driving innovation and unlocking commercial value in the medical devices and life science sectors. He has a proven track record of guiding large multidisciplinary teams working at the junction of science and engineering to design cost effective, scalable and market competitive solutions. Throughout his career Sergey has directed the end-to-end product design and development lifecycle, from innovation through manufacturing.
Sergey acquired expertise in the point of care diagnostics industry, serving as technical lead for Abbott’s i-STAT blood analysis platform, which has an installed base of over 200,000 instruments globally. With extensive experience in imaging devices, Sergey led the development of a hematology fluorescence imaging platform utilizing waterless microfluidic cartridge-based technology. Recognizing the potential of microfluidic technology for low cost high thruput blood analysis instrumentation, Sergey led a team to develop a dry multiplexed immunoassay platform for infectious disease testing in donor screening application. Sergey is skilled at assembling top-performing multidisciplinary teams and takes an integrated approach to development.

Chief FInancial Officer
Charlie Robertson possesses a wealth of experience in operational and financial leadership in the point of care diagnostics industry, specializing in integrated business planning, program management and financial analysis. He has led multiple enterprise-wide cross-functional product development and commercial launches including Abbott’s next generation i-STAT Alinity platform and a multiplex blood test for mild Traumatic Brain Injury.
After starting his career as a mechanical engineer in medical device contract manufacturing, Charlie received his MBA and transitioned into finance to support the scale up of a start-up business acquired by Abbott. Having gained diverse technical and business experience, he moved into general management to help drive innovation in the product portfolio. He has a passion for building high-functioning cross-functional teams that move decisively to develop products from concept-to-launch, including rolling up his sleeves to define R&D plans, quality and regulatory strategies, manufacturing transfer, and go-to-market strategies.
Advisory Team

Stan Lapidus is an entrepreneur and inventor with 37 patents. He founded and led two prominent cancer early-detection companies, Cytyc and Exact Sciences. He is the inventor of Cytyc’s ThinPrep Pap test for early detection of cervical cancer, which is the global market leader for cervical cancer screening. He is a co-inventor of the Cologuard test for early detection of colorectal cancer, the flagship product of Exact Sciences.
Stan also founded and led SynapDx and Helicos Biosciences, and currently serves on the board of multiple diagnostic and medical device companies focused on the early detection and diagnosis of disease. He was an instructor at MIT from 2001 to 2017 and is a Fellow of the American Institute of Medical and Biological Engineering.

Charlie Kim is a life science executive with expertise in technology development and applications in translational research. He most recently built and led Molecular Science at Verily, a spin-out from Google[x]. He led teams responsible for innovating molecular and computational platforms, including Immune Profiler and Virtual Stainer, which were deployed in numerous biopharma partnerships for drug target prioritization, biomarker discovery, and mechanism-of-action studies across autoimmunity, immuno-oncology, and infectious disease.
He also directed biospecimen operations and analysis — including whole blood processing — for large-scale longitudinal studies such as PRESCO, a multi-site observational study on long COVID-19 outcomes, and Project Baseline, a longitudinal multimodal study of the transition from health to disease. He previously served on the faculty of the UCSF Department of Medicine and earned his PhD in Microbiology and Immunology from Stanford University, where he pioneered the application of genomic and bioinformatic approaches to the study of infectious disease and immunology.

Joydeep Goswami is an experienced executive with a strong background in running large global P&Ls as well as a C-suite leader for finance, strategy, and corporate development. Most recently, he served as Chief Financial Officer and Chief Strategy & Corporate Development Officer at Illumina, Inc., where he managed financial functions and led corporate strategy, M&A, licensing, and partnerships.
Before Illumina, Joydeep was President of Thermo Fisher Scientific’s Clinical NGS and Oncology business, focusing on NGS adoption in clinical settings. He has held senior global and international roles in businesses related to Pharma, biotech, diagnostics, and research tools and services at companies including Life Technologies, Invitrogen, and Thermo Fisher. Additionally, Joydeep was a consultant at McKinsey & Co. serving the Pharma/ Biotech, Medtech and Private Equity industries. He holds an M.S. and Ph.D. in Chemical Engineering and an MBA from MIT, along with a Bachelor’s in Chemical Engineering from IIT. He also serves on the board of Biolife Solutions, Inc.